Cabaletta Bio (CABA) risk factors, FY2025 10-K

Risks Related to Clinical Development

1. 01We are early in our development efforts. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed
2. 02maintaining a continued acceptable safety profile of our products following licensure90% rewritten
3. 03managing costs of inputs and other supplies while scaling production
4. 04Preconditioning regimens, as currently implemented in several of our clinical trials, may increase the risk of adverse side effects and impact our ability to accurately assess the efficacy of our product candidates
5. 05We have never successfully completed any clinical trials, and we may be unable to do so for any product candidates we develop
6. 06Our registrational trials may rely on a single-arm design and an external control; if regulatory authorities determine that the external control is unsuitable, we may be unable to obtain approval on our anticipated timelines, or at allNew
7. 07while off immunomodulators and on no or low‑dose steroids—and we intend to rely on a retrospective analysis of a myositis patient registry to estimate control response ratesNew
8. 08If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates
9. 09a decline in our share price

Risks Related to the Industry

1. 10Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences
2. 11Our preclinical studies and clinical trials may fail to demonstrate the safety, potency and purity of any of our product candidates, which would prevent or delay regulatory approval and commercialization
3. 12Interim, topline or preliminary data from any preclinical studies or clinical trials that we conduct may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data73% rewritten
4. 13As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluatedNew
5. 14The increasing use of social media platforms presents new risks and challenges22% rewritten
6. 15We may encounter substantial delays in our clinical trials or may not be able to conduct our trials on the timelines we expect or at all
7. 16Monitoring safety of patients receiving our product candidates will be challenging, which could adversely affect our ability to obtain regulatory approval and commercialize our product candidates
8. 17If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
9. 18the ability of patients to meet the complex follow-up requirements of the clinical trial

Risks Related to Sales, Marketing and Competition

1. 19The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small
2. 20We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively29% rewritten
3. 21Even if we obtain regulatory approval of our product candidates, the products may not gain the market acceptance among physicians, patients, hospitals, treatment centers and others in the medical community necessary for commercial success
4. 22the effectiveness of our sales and marketing efforts

Risks Related to Business Development

1. 23We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize development of certain product candidates, which may prove to be wrong and may adversely affect our business
2. 24it may take greater human and financial resources than we will possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify and expand our product portfolio
3. 25If we fail to develop additional product candidates, our commercial opportunity will be limited
4. 26We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
5. 27We expect to grow the size of our organization, and we may experience difficulties in managing this growth
6. 28improving our operational, financial and management controls, reporting systems and procedures33% rewritten
7. 29that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at allNew
8. 30Business disruptions, including due to natural disasters, global conflicts or political unrest, could seriously impact our operations, research and trials and harm our future revenue and financial condition75% rewritten

Risks Related to Past Financial Condition

1. 31We have incurred net losses in every period since our inception and anticipate that we will incur substantial net losses over the next several years, and may never achieve or maintain profitability
2. 32add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts, as well as to support our operations as a public company
3. 33there are any third-party challenges to our intellectual property or we need to defend against any intellectual property-related claim
4. 34We have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability, and we may face significant challenges and expense as we test our product candidates and build our capabilities21% rewritten
5. 35We have not generated any revenue from our product candidates and our ability to generate revenue from product sales and become profitable depends significantly on our success in a number of areas
6. 36our ability to establish and enforce intellectual property rights in and to our product candidates or any future product candidates

Risks Related to Future Financial Condition

1. 37the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own
2. 38Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall82% rewritten
3. 39sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stockNew
4. 40Our outstanding common stock warrants may not be exercised, and we may not receive any additional funds upon the exercise of such warrantsNew
5. 41We will not receive any meaningful amount of additional funds upon the exercise of the pre-funded warrants; however, any exercise would increase the number of shares of our common stock eligible for future resale in the public market and result in dilution to our stockholdersNew

Risks Related to Our Intellectual Property

1. 42the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners
2. 43If our efforts to protect the proprietary nature of the intellectual property related to our current and any future product candidates are not adequate, we may not be able to compete effectively in our market
3. 44We may not be able to protect our intellectual property rights throughout the world
4. 45We or our licensors may be subject to claims challenging the inventorship or ownership of the patents and other intellectual property that we own or license
5. 46We may become involved in lawsuits to protect or enforce our patent rights or other intellectual property rights, which could be expensive, time consuming and unsuccessful
6. 47Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
7. 48If we are unable to protect the confidentiality of trade secrets, our business and competitive position would be harmed
8. 49Patent term may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
9. 50We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property
10. 51We may become subject to claims that we are infringing certain third-party patents or other third-party intellectual property rights, any of which may prevent or delay our development and commercialization efforts and have a material adverse effect on our business
11. 52Intellectual property rights do not necessarily address all potential threats

Risks Related to Our Reliance on Third Parties

1. 53We currently, and will likely continue to, rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates28% rewritten
2. 54We intend to rely on third parties to manufacture our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if licensed
3. 55Any contract manufacturers that we engage may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our product candidates
4. 56Our third-party manufacturers could breach or terminate their agreement with us64% rewritten
5. 57its approval in the future, we may need to find alternative manufacturing facilities, which would negatively impact our ability to develop, obtain regulatory approval for or market our product candidates, if licensedNew
6. 58We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements
7. 59We may not realize the benefits of acquired assets or other strategic transactions, including any transactions whereby we acquire or license manufacturing and other advanced technologies48% rewritten
8. 60possible write-offs or impairment charges relating to acquired businesses or joint ventures

Risks Related to Manufacturing and Supply

1. 61We are reliant on Minaris and Lonza for our current manufacturing activities and termination would disrupt normal business operations, and we intend to continue to rely on other third parties for our future manufacturing needs prior to establishing our own manufacturing facility50% rewritten
2. 62The manufacturing process for any products that we may develop is subject to the FDA approval process, and we will need to contract with manufacturers who can meet all applicable FDA requirements on an ongoing basis
3. 63The manufacture of viral vectors is complex and variable, and there are a limited number of manufacturers able to supply us with viral vectors
4. 64If we are to operate our own manufacturing facility, significant resources will be required and we may fail to successfully operate our facility, which could adversely affect our clinical trials and the commercial viability of our product candidates
5. 65The manufacture of biopharmaceutical products is complex and requires significant expertise, and can be impacted by resource constraints, labor disputes and workforce limitations
6. 66We are dependent upon the availability of specialty raw materials and the production capabilities of small manufacturers to source the components of our product candidates
7. 67We may encounter difficulties in production, particularly with respect to process development or scaling up of our manufacturing capabilities. If we encounter such difficulties, our ability to provide supply of our CAR T cells for clinical trials or for commercial purposes could be delayed or stopped
8. 68If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages
9. 69Changes in product candidate manufacturing or formulation may result in additional costs or delay, which could adversely affect our business, results of operations and financial condition

Risks Related to Government Regulation

1. 70The regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates
2. 71manufacturing sufficient quantities of qualified materials under cGMPs and applying them on a patient by patient basis for use in clinical trials
3. 72We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition
4. 73If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired
5. 74the approval policies or regulations of the FDA or other foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval93% rewritten
6. 75Even though we may apply for orphan drug designation for our product candidates, we may not be able to obtain orphan drug marketing exclusivity
7. 76The FDA has granted rare pediatric disease designation to rese-cel for the treatment of juvenile dermatomyositis. However, a marketing application for rese-cel or any other product candidate, if approved, may not meet the eligibility criteria for a priority review voucher
8. 77the BLA is approved for a different adult indication than the rare pediatric disease for which rese-cel is designated20% rewritten
9. 78A fast track designation by the FDA, even if granted, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our current product candidate and any future product candidates will receive marketing approval
10. 79Although we may pursue expedited regulatory approval pathways for a product candidate, it may not qualify for expedited development or, if it does qualify for expedited development, it may not actually lead to a faster development or regulatory review or approval process39% rewritten
11. 80Significant political, trade, regulatory developments, and other circumstances beyond our control, could have a material adverse effect on our financial condition or results of operations48% rewritten

Risks Related to Ongoing Regulatory Obligations

1. 81injunctions or the imposition of civil or criminal penalties
2. 82If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
3. 83Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements

Risks Related to Healthcare

1. 84Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if licensed, profitably68% rewritten
2. 85the section titled “Business—Government regulation—Pricing and Reimbursement” included in this Annual Report on Form 10-KNew
3. 86Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations79% rewritten
4. 87the availability of capitalNew
5. 88other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our productsNew

Risks Related to Data Privacy and Security

1. 89Data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information59% rewritten
2. 90addition, any such action, particularly to the extent we were found to be guilty of violations or otherwise liable for damages, would damage our reputation and adversely affect our business, financial condition and results of operationsNew
3. 91Interruptions in the availability of server systems or communications with internet or cloud-based services, or failure to maintain the security, confidentiality, accessibility or integrity of data stored on such systems, could harm our business79% rewritten

Risks Related to Ownership Generally

1. 92Our principal stockholders and management own a large percentage of our stock and could be able to exert significant control over matters subject to stockholder approval57% rewritten
2. 93If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed
3. 94The dual class structure of our common stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions
4. 95Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall78% rewritten

Risks Related to our Charter and Bylaws

1. 96Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management
2. 97the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock
3. 98Our amended and restated bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees

Risks Related to Tax

1. 99Changes in tax laws could adversely affect our business and financial condition82% rewritten
2. 100Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and our financial condition and results of operations
3. 101disruptions, any of which could adversely impact our business operations or delay necessary interactions with local regulators, ethics committees and other important agencies and contractorsNew
4. 102The price of our stock may be volatile, and you could lose all or part of your investment
5. 103other events or factors, many of which are beyond our control
6. 104Our business is affected by macroeconomic conditions, including rising inflation, interest rates and supply chain constraints
7. 105We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock
8. 106We are a “smaller reporting company,” and we cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make our common stock less attractive to investors
9. 107Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
10. 108We could be subject to significant legal proceedings which may adversely affect our results of operations or financial condition
11. 109If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
12. 110The U.S. Congress or the current administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our businessNew